X

Drug Profile

JL 15003

Alternative Names: JL-15003

Latest Information Update: 10 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator JECHO Biopharmaceuticals
Class Antineoplastics; Immunotherapies; Oncolytic viruses
Mechanism of Action Cell death stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Glioblastoma

Most Recent Events

10 Jul 2023 Phase-I clinical trials in Glioblastoma (Second-line therapy or greater) in China (Parenteral) before July 2023 (JECHO Biopharmaceuticals pipeline, July 2023)
31 Dec 2021 Preclinical trials in Glioblastoma in China (Parenteral)
31 Dec 2021 China's NMPA approves IND application of JL 15003 in Glioblastoma (Second-line therapy or greater) in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com